Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label follow-up study of certolizumab pegol plus DMARDs in rheumatoid arthritis (C87076 extension)
2007-000830-38Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2008
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Primary endpoints: Long-term safety of certolizumab pegol + DMARDs and Long-term efficacy of certolizumab pegol + DMARDs. Started Jul 2008; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-000830-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000830-38.